Ex-GSK Exec to Steer Sangamo; Lanphier Switches Roles

Xconomy San Francisco — 

Edward Lanphier is retiring as the president and CEO of Sangamo Biosciences (NASDAQ: SGMO), paving the way for Alexander Macrae—a former GlaxoSmithKline and later Takeda executive—to take over the Richmond, CA-based gene editing company. Macrae began in his new role today, while Lanphier will become chairman of Sangamo’s board after the company’s annual shareholder meeting on June 14.